APL-502 (PD-L1)

APL-502: Anti Programmed Death Ligand-1

Formerly CBT-502

APL-502 is a novel IgG1 humanized monoclonal antibody against the Programmed Death Ligand-1 (PD-L1) membrane receptor. APL-502 shows significant sequence divergence in complementarity-determining regions (CDRs) from other anti- PD-L1 antibodies in the market today. Pre-clinical pharmacodynamics and toxicology studies of APL-502 demonstrated pharmacological activity and the agent is well tolerated at effective doses with a wide margin of safety. In vitro studies have demonstrated binding affinity while in-vivo efficacy and safety data in the murine models compared favorably to atezolizumab.

PD‑1 protein is expressed on immune cells called T cells normally acting as a type of "off switch" that helps keep the T cells from attacking other cells in the body (e.g. healthy cells). PD‑L1 protein is expressed on some normal cells and on cancer cells. PD-1 binds to PD‑L1 and this interaction signals T cells to leave the other cell alone and not attack it. This protects normal, healthy cells from immune attack. But, some cancer cells hijack PD‑L1 expression so the PD-1 expressing T cell adopts a “don’t attack” state which helps the cancer cells hide from the immune system and subsequently grow. Therapies that target PD-1 stop it from interacting with PD-L1. Similarly, therapies that target PD-L1 prevent PD-1 from interacting with it. This allows the T cell to attack cancer cells in the body and prevent them from hiding.

Apollomics retains worldwide rights to APL-502 outside of China.

Clinical Trials

APL-502 is currently being evaluated in one solid tumor trial. For additional information, please click on the trial link below.

China Partner & Clinical Trials:

Chia Tai TianQing Pharmaceutical Group (CTTQ Pharma) has development rights in China for APL-502 where it is referred to as      TQ-B2450.

Trial Details
Type: Single Agent
Phase: 1
Indication: Solid Tumors
Trial: TBA

Posters & Publications

Posters and Publications on our assets can be found here.